These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 16312175)
1. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Mocroft A; Rockstroh J; Soriano V; Ledergerber B; Kirk O; Vinogradova E; Reiss P; Katlama C; Phillips AN; Lundgren JD; Antivir Ther; 2005; 10(7):779-90. PubMed ID: 16312175 [TBL] [Abstract][Full Text] [Related]
2. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065 [TBL] [Abstract][Full Text] [Related]
3. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN; AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843 [TBL] [Abstract][Full Text] [Related]
4. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD; AIDS Res Hum Retroviruses; 2005 Sep; 21(9):743-52. PubMed ID: 16218797 [TBL] [Abstract][Full Text] [Related]
5. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD; AIDS Res Hum Retroviruses; 2005 Jun; 21(6):527-36. PubMed ID: 15989457 [TBL] [Abstract][Full Text] [Related]
6. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J; J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951 [TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. Cacoub P; Rosenthal E; Halfon P; Sene D; Perronne C; Pol S J Viral Hepat; 2006 Oct; 13(10):678-82. PubMed ID: 16970599 [TBL] [Abstract][Full Text] [Related]
8. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Worm SW; Sabin C; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; Monforte AD; Friis-Møller N; Kirk O; Fontas E; Weller I; Phillips A; Lundgren J J Infect Dis; 2010 Feb; 201(3):318-30. PubMed ID: 20039804 [TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246 [TBL] [Abstract][Full Text] [Related]
11. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection. Cooper CL; Mills E Int J STD AIDS; 2007 Aug; 18(8):546-50. PubMed ID: 17686217 [TBL] [Abstract][Full Text] [Related]
12. Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study. Vo TT; Ledergerber B; Keiser O; Hirschel B; Furrer H; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Weber R; J Infect Dis; 2008 Jun; 197(12):1685-94. PubMed ID: 18513155 [TBL] [Abstract][Full Text] [Related]
13. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
14. [Coinfection with hepatitis C virus and HIV]. Ruys TA; Reesink HW; Lange JM Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2056-60. PubMed ID: 14606352 [TBL] [Abstract][Full Text] [Related]
15. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551 [TBL] [Abstract][Full Text] [Related]
16. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India. Gupta SB; Pujari SN; Joshi SR; Patel AK; J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. Nyirenda M; Beadsworth MB; Stephany P; Hart CA; Hart IJ; Munthali C; Beeching NJ; Zijlstra EE J Infect; 2008 Jul; 57(1):72-7. PubMed ID: 18555534 [TBL] [Abstract][Full Text] [Related]
18. HIV and hepatitis C coinfection. Matthews GV; Dore GJ J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597 [TBL] [Abstract][Full Text] [Related]
19. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy. Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968 [TBL] [Abstract][Full Text] [Related]
20. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O; AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]